Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KZIA
KAZIA THERAPEUTICS LTD ADR
NASDAQ
$13.58
▼ DOWN 19.64% (-3.32)

KEY STATISTICS

Market Cap$22.00 M
52w High$17.40
52w Low$4.86
Dividend Yield—
Frequency—
P/E-2.85
Volume1.18M
Shares Out.1.62M

COMPANY

LEADERSHIP

John Edwin Friend
CHIEF EXECUTIVE
John Edwin Friend

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 6, 1999
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
6

PRICE TARGET

Target High$34.00
Target Low$25.00
Target Median$30.50
Target Consensus$30.00

UPCOMING EARNINGS

DateSep 4, 2026
DayFriday
Rev. Est.$133.52K
SEP
4
FRI

SPLIT RECORD

DATETYPERATIO
2025-04-17Reverse1:5
2025-03-21Reverse1:5
2024-10-28Reverse1:10
2020-10-02Forward1041:1000
2017-07-14Reverse1:4
2013-01-28Forward1519:500
2012-01-03Reverse1:5

PRICE

$13.58 ▼ DOWN 19.64% (−$3.32)
OVERLAYS
$13.50$14.25$15.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.58

About Kazia Therapeutics Ltd ADR

https://www.kaziatherapeutics.com ↗

Kazia Therapeutics Limited, an Australian biotech specializing in oncology, develops anti-cancer drugs like Paxalisib for glioblastoma and EVT801 for various cancers.

INDUSTRY

Biotechnology

A PRODUCT KAZIA THERAPEUTICS LTD ADR IS KNOWN FOR

Paxalisib
Paxalisib

Paxalisib is an investigational brain-penetrant PI3K/Akt/mTOR inhibitor developed by Kazia for glioblastoma, currently in advanced clinical trials targeting newly diagnosed cases.

COMPETITORS

COMPETITOR
CNSP COMPARE
KPTI COMPARE
MBRX COMPARE

Revenue by Products

IconPRODUCTFY2021FY2024FY2025
Licensing Revenue$15.18M $2.3M ▼$0 ▼

Revenue by Geography

MapREGIONFY2021FY2025
CHINA$10.01M —
Swedan$5.18M —
ISRAEL— $42K

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
APIE
0.00% · 3.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.01%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Cordasco Financial Network
125 sh · $1K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Coffey Steven R. S.
Purchase · 100.0K shares
2026-01-08
★
OFFICER: CHIEF EXECUTIVE OFFICER
Friend John E. II
Purchase · 500.0K shares
2026-01-08
★
OFFICER: CHIEF EXECUTIVE OFFICER
Friend John E. II
Sale · 150.0K shares
2026-01-08
★
OFFICER: VP, FINANCE AND CONTROLLER
Bonacorda Jeffrey
Purchase · 150.0K shares
2026-01-08

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS
BTIG BUY HC Wainwright & Co. BUY Maxim Group BUY

SECTORS PEERS

PEERPRICE
CNSP$5.52COMPARE
SNGX$0.38COMPARE
SILO$2.54COMPARE
CMND$1.76COMPARE
INM$1.38COMPARE
BDRX$0.87COMPARE
GRI$1.92COMPARE